MARCH 2024

  • Game’s afoot in bladder cancer research

    March 2024—Like identifying the shift in battle that leads to victory, or the battle that wins the war—let alone declaring a war’s ultimate victor—it’s hard to gauge the whens, ifs, and hows that mark progress in medicine. For those who are deeply rooted in bringing advances to testing in urothelial cancers, current research is flourishing and flummoxing. In early and late stage, both for bladder and upper tract disease, recently approved therapies are leading to better outcomes for patients. More immunotherapies and antibody-drug conjugates are on their way, and with them come new options for testing. But as with any cancer, researchers follow numerous promising paths, knowing that some will dead-end and others will succeed primarily (albeit usefully) in raising more questions. Nevertheless, they continue to rally the work forward, with multiple breaches, and Agincourt, ever in sight. For experts such as David McConkey, PhD, progress will best be measured by how regularly precision makes its way into the clinical setting.

    Read More »
  • From training to first jobs, can the transition be made easier?

    March 2024—Pathology trainees and training programs vary, as do first jobs, but the first year in pathology practice is generally said to be a tough one, largely because of the transition to fully independent case sign-out.

  • In diabetes patients, biomarker use for early-stage HF

    March 2024—For patients with type 2 diabetes, the cardiac biomarkers are a better predictor of early-stage heart failure than conventional risk prediction scores. “We need to use biomarkers,” says Petr Jarolim, MD, PhD.

  • Dr. Leung

    Survey probes staff shortage in genomics labs

    March 2024—From a technologist workforce perspective, clinical genomics laboratories are in trouble. “It’s truly a crisis,” said Marco Leung, PhD, clinical director of the Steve and Cindy Rasmussen Institute for Genomic Medicine at Nationwide Children’s Hospital in Columbus, Ohio.

Image Credits: [do_widget id=enhancedtextwidget-12].

Video Spotlight

CAP TODAY Roundtables

CAP TODAY WEBINARS

Image Credits: [do_widget id=enhancedtextwidget-12].

REGISTER NOW

  • Register for our upcoming webinar

    Liquid Biopsy and Concurrent Testing Strategies for Patients with Metastatic NSCLC
    Thursday, April 11, 2024, 12:00 PM–1:00 PM ET
    Webinar presenter Zin Htway, PhD Supervisor and Operations Manager, Anatomic Pathology as HCA, Los Robles Hospital and Medical Center, will discuss the impact of liquid biopsy and concurrent biomarker testing for the appropriate care of patients with NSCLC​. Dr. Htway will review the potential benefits of integrating liquid biopsy with standard-of-care tissue testing on turnaround time and identification of patients with actionable biomarkers in metastatic NSCLC​ and explore patient case scenarios that demonstrate potential successes and implementation considerations for concurrent liquid biopsy integration in metastatic NSCLC​.

    Read More »
  • Register for our upcoming webinar

    Virtual Roundtable: Optimizing Testing for the Diagnosis of Systemic Mastocytosis

    June 25, 2024, 1:00 PM–2:00 PM ET

    Webinar presenters Robyn Scherber, MD, MPH Hematologist UT Health SA, Medical Director Blueprint Medicines; Anton Rets, MD, PhD Associate Professor University of Utah, Medical Director Hematopathology and Immunohistochemistry; Nathan A. Boggs, MD, PhD Assistant Professor of Medicine, Uniformed Services University Allergy Division Director will discuss the barriers and possible solutions to screening for and diagnosing Systemic Mastocytosis (SM) and recommendations that will empower cross-functional laboratory stakeholders to implement changes that can help improve the diagnosis of SM.

Image Credits: [do_widget id=enhancedtextwidget-12].

AMP Case Reports

MARCH 2024

  • Game’s afoot in bladder cancer research

    March 2024—Like identifying the shift in battle that leads to victory, or the battle that wins the war—let alone declaring a war’s ultimate victor—it’s hard to gauge the whens, ifs, and hows that mark progress in medicine. For those who are deeply rooted in bringing advances to testing in urothelial cancers, current research is flourishing and flummoxing. In early and late stage, both for bladder and upper tract disease, recently approved therapies are leading to better outcomes for patients. More immunotherapies and antibody-drug conjugates are on their way, and with them come new options for testing. But as with any cancer, researchers follow numerous promising paths, knowing that some will dead-end and others will succeed primarily (albeit usefully) in raising more questions. Nevertheless, they continue to rally the work forward, with multiple breaches, and Agincourt, ever in sight. For experts such as David McConkey, PhD, progress will best be measured by how regularly precision makes its way into the clinical setting.

    Read More »
  • From training to first jobs, can the transition be made easier?

    March 2024—Pathology trainees and training programs vary, as do first jobs, but the first year in pathology practice is generally said to be a tough one, largely because of the transition to fully independent case sign-out.

  • In diabetes patients, biomarker use for early-stage HF

    March 2024—For patients with type 2 diabetes, the cardiac biomarkers are a better predictor of early-stage heart failure than conventional risk prediction scores. “We need to use biomarkers,” says Petr Jarolim, MD, PhD.

  • Dr. Leung

    Survey probes staff shortage in genomics labs

    March 2024—From a technologist workforce perspective, clinical genomics laboratories are in trouble. “It’s truly a crisis,” said Marco Leung, PhD, clinical director of the Steve and Cindy Rasmussen Institute for Genomic Medicine at Nationwide Children’s Hospital in Columbus, Ohio.

Image Credits: [do_widget id=enhancedtextwidget-12].

Video Spotlight

CAP TODAY Roundtables

CAP TODAY WEBINARS

Image Credits: [do_widget id=enhancedtextwidget-12].

REGISTER NOW

  • Register for our upcoming webinar

    Liquid Biopsy and Concurrent Testing Strategies for Patients with Metastatic NSCLC
    Thursday, April 11, 2024, 12:00 PM–1:00 PM ET
    Webinar presenter Zin Htway, PhD Supervisor and Operations Manager, Anatomic Pathology as HCA, Los Robles Hospital and Medical Center, will discuss the impact of liquid biopsy and concurrent biomarker testing for the appropriate care of patients with NSCLC​. Dr. Htway will review the potential benefits of integrating liquid biopsy with standard-of-care tissue testing on turnaround time and identification of patients with actionable biomarkers in metastatic NSCLC​ and explore patient case scenarios that demonstrate potential successes and implementation considerations for concurrent liquid biopsy integration in metastatic NSCLC​.

    Read More »
  • Register for our upcoming webinar

    Virtual Roundtable: Optimizing Testing for the Diagnosis of Systemic Mastocytosis

    June 25, 2024, 1:00 PM–2:00 PM ET

    Webinar presenters Robyn Scherber, MD, MPH Hematologist UT Health SA, Medical Director Blueprint Medicines; Anton Rets, MD, PhD Associate Professor University of Utah, Medical Director Hematopathology and Immunohistochemistry; Nathan A. Boggs, MD, PhD Assistant Professor of Medicine, Uniformed Services University Allergy Division Director will discuss the barriers and possible solutions to screening for and diagnosing Systemic Mastocytosis (SM) and recommendations that will empower cross-functional laboratory stakeholders to implement changes that can help improve the diagnosis of SM.

Image Credits: [do_widget id=enhancedtextwidget-12].

AMP Case Reports

MARCH 2024

  • Game’s afoot in bladder cancer research

    March 2024—Like identifying the shift in battle that leads to victory, or the battle that wins the war—let alone declaring a war’s ultimate victor—it’s hard to gauge the whens, ifs, and hows that mark progress in medicine. For those who are deeply rooted in bringing advances to testing in urothelial cancers, current research is flourishing and flummoxing. In early and late stage, both for bladder and upper tract disease, recently approved therapies are leading to better outcomes for patients. More immunotherapies and antibody-drug conjugates are on their way, and with them come new options for testing. But as with any cancer, researchers follow numerous promising paths, knowing that some will dead-end and others will succeed primarily (albeit usefully) in raising more questions. Nevertheless, they continue to rally the work forward, with multiple breaches, and Agincourt, ever in sight. For experts such as David McConkey, PhD, progress will best be measured by how regularly precision makes its way into the clinical setting.

    Read More »
  • From training to first jobs, can the transition be made easier?

    March 2024—Pathology trainees and training programs vary, as do first jobs, but the first year in pathology practice is generally said to be a tough one, largely because of the transition to fully independent case sign-out.

  • In diabetes patients, biomarker use for early-stage HF

    March 2024—For patients with type 2 diabetes, the cardiac biomarkers are a better predictor of early-stage heart failure than conventional risk prediction scores. “We need to use biomarkers,” says Petr Jarolim, MD, PhD.

  • Dr. Leung

    Survey probes staff shortage in genomics labs

    March 2024—From a technologist workforce perspective, clinical genomics laboratories are in trouble. “It’s truly a crisis,” said Marco Leung, PhD, clinical director of the Steve and Cindy Rasmussen Institute for Genomic Medicine at Nationwide Children’s Hospital in Columbus, Ohio.

Image Credits: [do_widget id=enhancedtextwidget-12].

Video Spotlight

CAP TODAY Roundtables

CAP TODAY WEBINARS

Image Credits: [do_widget id=enhancedtextwidget-12].

REGISTER NOW

  • Register for our upcoming webinar

    Liquid Biopsy and Concurrent Testing Strategies for Patients with Metastatic NSCLC
    Thursday, April 11, 2024, 12:00 PM–1:00 PM ET
    Webinar presenter Zin Htway, PhD Supervisor and Operations Manager, Anatomic Pathology as HCA, Los Robles Hospital and Medical Center, will discuss the impact of liquid biopsy and concurrent biomarker testing for the appropriate care of patients with NSCLC​. Dr. Htway will review the potential benefits of integrating liquid biopsy with standard-of-care tissue testing on turnaround time and identification of patients with actionable biomarkers in metastatic NSCLC​ and explore patient case scenarios that demonstrate potential successes and implementation considerations for concurrent liquid biopsy integration in metastatic NSCLC​.

    Read More »
  • Register for our upcoming webinar

    Virtual Roundtable: Optimizing Testing for the Diagnosis of Systemic Mastocytosis

    June 25, 2024, 1:00 PM–2:00 PM ET

    Webinar presenters Robyn Scherber, MD, MPH Hematologist UT Health SA, Medical Director Blueprint Medicines; Anton Rets, MD, PhD Associate Professor University of Utah, Medical Director Hematopathology and Immunohistochemistry; Nathan A. Boggs, MD, PhD Assistant Professor of Medicine, Uniformed Services University Allergy Division Director will discuss the barriers and possible solutions to screening for and diagnosing Systemic Mastocytosis (SM) and recommendations that will empower cross-functional laboratory stakeholders to implement changes that can help improve the diagnosis of SM.

Image Credits: [do_widget id=enhancedtextwidget-12].

AMP Case Reports

CAP TODAY
X